About Nanjing King-Friend Biochemical Pharmaceutical Company

The company was listed on the Shanghai Stock Exchange on July 19, 2017. The company has the world's leading isolator production line, high-end sterile injection production technology, and a global quality system certified by China, the United States, Europe, Japan, Brazil, etc. It has world-class production and development speed, global quality awareness, and sales capacity rooted in the US. At the same time, it can also provide injectable CDMO services with the Chinese and US markets as the core and covering the world. The company has established a new bioinnovative drug division to gather innovative talents from around the world, push the company towards innovation and internationalization, and build a world-class biopharmaceutical company. The company is a pharmaceutical enterprise integrating R&D, production and sales of pharmaceuticals. It actively lays out the fields of chemicals and biopharmaceuticals, and has established a rich product pipeline covering cardiovascular, neurological, anesthetic, antitumor preparations, surgical aids, and other high-value-added sterile injections. It is a supplier of various types of injections in the global market. The main products are fluvirizine injections, carboplatin injections, azacitidine injections, busulfan injections, melphalan hydrochloride for injections, fluorouracil injections, etc. as antineoplastic preparations. Company honors: Jiangsu Certified Enterprise Technology Center, Jiangsu Open Economy Advanced Enterprise, Nanjing Municipal Key Agricultural Commercialization Leading Enterprise, etc.